Fig. 3From: Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19Post-hoc analysis: time to symptom alleviation (FLU-PRO user manual definition). Based on data through Day 21, as shown in the end of study Week 24 database. FLU-PRO inFLUenza Patient-Reported Outcome, IV intravenousBack to article page